News | September 17, 2024
Panacea Biotec and Sanofi reached settlement agreement for Shan6
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
Total investment incurred for setting up the new R&D Rs 250 crore
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
This case is an isolated case, similar to the earlier 30 cases reported in India from July 2022 onwards
The patient has been isolated in a designated hospital and is currently stable
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Subscribe To Our Newsletter & Stay Updated
